Researchers from the University of California and Brigham and Women’s Hospital in Boston recently examined adherence among Medicaid beneficiaries with lupus to prescribed medications and found the patients were not following treatment plans, putting themselves at risk for poor outcomes.
Cell based therapies are a growing interest in all areas of medicine as they are viewed as long term solutions rather than temporary fixes. A recent journal article highlights progress made in better understanding the potential for two basic types of adult stem cells.
Lupus nephritis, which can damage and scar the kidneys, is one of the most common and serious complications of lupus. This new study suggests that with the right induction regimen, it may be possible to avoid maintenance (long-term) treatment with oral steroids.
A new study sheds light on the specific effects of drug treatments versus disease activity as risk factors for lymphoma, a type of cancer, among people with lupus.
The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.